LADXD

LadRx Corp

USOTC

Add Alert

208

LADXD

LadRx Corp

USOTC

Add Alert

208

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating

Older

Renee

05/16/23 8:59 PM

Post #7,747

LADX one for 100 reverse split:

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes

potofgold

05/10/23 5:31 PM

Post #7,746

News release out. Reverse split coming next week.

Renee

10/05/22 6:01 PM

Post #7,745

CytRx Corp., CYTR, changed to LadRx Corp., LADX:

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes

learningcurve2020 Free

06/12/22 6:50 PM

Post #7,744

Bye bye. Another retail crushing rs. Rinse and repeat. Next CEO!!!

Approval of an amendment to our Restated Certificate of Incorporation (“Certificate of Incorporation”) to effect, at the discretion of the Board but prior to the one-year anniversary of the date on which the reverse stock split is approved by the Company’s stockholders at the Annual Meeting, a reverse stock split of all of the outstanding shares of our Common Stock at a ratio in the range of 1-for-2 to 1-for-100, with such ratio to be determined by the Board in its discretion and included in a public announcement (the “Reverse Stock Split Proposal”)

Jagz16

04/26/22 10:01 AM

Post #7,743

Wth happened!! 15 cents??

willlbone

04/19/22 1:14 PM

Post #7,742

Volume selling today..

learningcurve2020 Free

04/19/22 9:35 AM

Post #7,741

Re: #7,740: @SpaceTimeRift777 - It was always a Scam

Do we think Kriegsman also snowed Snowdy?

SpaceTimeRift777 Free

04/16/22 5:18 PM

Post #7,740

Re: #7,739: @Jagz16 - Starting to truly believe it’s a scam!! I’ve

It was always a Scam

Jagz16

04/13/22 12:50 PM

Post #7,739

Re: #7,738: @Banjo50 - IS THIS STOCK A SCAM OR WHAT???

Starting to truly believe it’s a scam!! I’ve lost thousands, believing in this crooked BS

Banjo50

03/01/22 3:50 AM

Post #7,738

IS THIS STOCK A SCAM OR WHAT??? I WANT THE TRUTH!!!

learningcurve2020 Free

01/04/22 1:40 PM

Post #7,737

Bravo!!! So long Kriegsman!

CytRx Corporation (OTCQB:CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development in oncology and neurodegenerative diseases, today announced that it has appointed Dr. Stephen Snowdy to the role of Chief Executive Officer, effective January 10, 2022. Dr. Louis Ignarro succeeded Steven A. Kriegsman as Chairman of the Board of Directors (the "Board") on January 3, 2022.

Dr. Snowdy is a scientist, serial entrepreneur and medical venture capitalist with two decades of experience in life science investing and executive management.

wrk_SATX

07/13/21 11:33 AM

Post #7,736

Dilute, dilute, dilute. Kreigsman needs his salary and rent. Rose gardens arn't cheap.

georgie18

06/30/21 9:12 AM

Post #7,735

CYTR...97...https://www.otcmarkets.com/stock/CYTR/news/CytRx-Comments-on-Orphazymes-Promising-24-Month-Interim-Trial-Results-of-Arimoclomol-for-Niemann-Pick-Disease-Type-C?id=309598

georgie18

06/24/21 7:06 AM

Post #7,734

CYTR...92...Bullish Descent Block Reversal Pattern to the Upside...Open Gap to fill in the $1.50/$2.50 range...

Chart...https://schrts.co/yuNqDEVZ ...

learningcurve2020 Free

06/23/21 8:55 AM

Post #7,733

Re: #7,732: @n4807g - LOL...This never showed a profit, cash incinerator, CYTR

And, all we get is a vague PR on the FDA issues with the trial. For all we know the trial never stood a chance from the very beginning. Just more research and OTC salaries.

n4807g

06/23/21 6:47 AM

Post #7,732

Re: #7,731: @learningcurve2020 - Kreigsman Special.

LOL...This never showed a profit, cash incinerator, CYTR made him rich at the retail investors expense. This company isn't worth $.02, but, as long as retail investors don't mind losing their shirt, the show will go on and the C suite crowd will further enrich themselves.....

learningcurve2020 Free

06/22/21 10:00 AM

Post #7,731

Kreigsman Special.

willlbone

06/21/21 3:07 PM

Post #7,730

FDA doesn't like their arimoclomol for Nose-Pick disease.

georgie18

06/21/21 10:18 AM

Post #7,729

Re: #7,728: @georgie18 - CYTR...$1.08...Back in on the dip and looking for

CYTR...Filled some at .88...:party:

georgie18

06/19/21 6:24 AM

Post #7,728

CYTR...$1.08...Back in on the dip and looking for this Open Gap to eventually fill...imo...we shall see...

Took quick profit on my $1.50 range alert in the $2 range but the move saw a $4.00 range move...

Dip based on this News...https://www.otcmarkets.com/stock/CYTR/news/CytRx-Notes-Orphazymes-Regulatory-Update-from-the-FDA-on-Arimoclomol-for-Niemann-Pick-Disease-Type-C?id=307976

Chart...https://schrts.co/WWgNhEPY ...

n4807g

06/18/21 5:48 AM

Post #7,727

Re: #7,721: @juas - so quiet here considering whats about to happen!

It'll be busy today....

n4807g

06/18/21 5:47 AM

Post #7,726

Oops.....

OTC_Buyer

06/14/21 11:38 PM

Post #7,725

Re: #7,702: @john sezso - For the newly curious about CYTR:

Those royalties about to be kickin in nicely

aristotelisonassis Free

06/10/21 3:07 PM

Post #7,724

blackpilled Free

06/10/21 2:19 PM

Post #7,723

Re: #7,721: @juas - so quiet here considering whats about to happen!

And what’s that??

coffee880

06/10/21 2:19 PM

Post #7,722

Re: #7,721: @juas - so quiet here considering whats about to happen!

What's happening?!?!? Whatever it is I like it!

juas

06/10/21 1:55 PM

Post #7,721

so quiet here considering whats about to happen!

georgie18

06/07/21 10:05 AM

Post #7,720

CYTR...$1.52...Bullish Harami forming on the daily...:partying_face:

georgie18

05/24/21 9:42 AM

Post #7,719

CYTR...$1.81...:party:
[9:41 AM]
georgie18 — 05/21/2021
CYTR...$1.65...Back in on the 200ma break...:party:

willlbone

05/12/21 10:26 AM

Post #7,718

Might buy some in the 80s today.

jacksira

05/11/21 4:31 PM

Post #7,717

Revenues, 32 MILLION shares, and Audited financials give me some of these shares please.

slow_feet

01/14/21 1:36 PM

Post #7,716

Re: #7,715: @eom7 - I have always thought they end up in NK

That's a logical guess. The chart says some knew something months ago as it's been accumulation ever since: buy, let it relax, buy, let it relax,...

I saw the same on CRIS last Summer, but it was for a different reason.

eom7

01/14/21 1:19 PM

Post #7,715

Re: #7,714: @slow_feet - Yeah, I think that last 8-K says we're

I have always thought they end up in NK

slow_feet

01/14/21 11:50 AM

Post #7,714

Re: #7,713: @eom7 - lol. They wont let me back in...

Yeah, I think that last 8-K says we're getting closer to M/A.

eom7

01/14/21 11:37 AM

Post #7,713

Re: #7,712: @slow_feet - Morning, Good trade!

lol. They wont let me back in...

slow_feet

01/14/21 8:09 AM

Post #7,712

Re: #7,711: @eom7 - Sold on shake... now I need to chase.

Morning,

Good trade!

I'm still holding from 12/14/20. I was tempted as well, but the last 8-K told me to wait/hold...

eom7

01/14/21 1:28 AM

Post #7,711

Re: #7,707: @slow_feet - It wasn't a criticism, merely a precursor for

Sold on shake... now I need to chase.

slow_feet

01/08/21 6:19 PM

Post #7,710

Re: #7,708: @john sezso - Got ya, It all became a little clearer,

Actually the word "parachute" is too harsh, more like "provision".

That the bod would allow the CFO to issue this provision in an 8-K, instead of just burying it in the next March 10-K (the 10-Qs are in 5/xx, 8/xx, 11/xx) implies a higher probability of an imminent M/A.

slow_feet

01/08/21 4:24 PM

Post #7,709

Re: #7,708: @john sezso - Got ya, It all became a little clearer,

john sezso Free

01/08/21 4:20 PM

Post #7,708

Got ya, It all became a little clearer, after I read the eighth line in the 8k a couple of times. >>>employment is terminated without “cause” following a “change in control” (as defined in his employment agreement))<<<<

slow_feet

01/08/21 7:53 AM

Post #7,707

Re: #7,706: @john sezso - I say tomato and some say potato,

It wasn't a criticism, merely a precursor for an expected occurrence...
a buy-out.

john sezso Free

01/08/21 7:50 AM

Post #7,706

I say tomato and some say potato, either way it is a pittance and CYTR has a bushel full of CA$H to pay it.

slow_feet

01/08/21 7:32 AM

Post #7,705

Re: #7,704: @john sezso - Mr. Caloz has entered into a new employment

Yes, and:

"...agree in Mr. Caloz’s employment agreement that if we do not offer to renew or extend the employment agreement we will continue to pay Mr. Caloz’s annual salary thereunder during the period commencing on expiration of the employment and ending on June 30, 2022 or the date he is employed by another employer, whichever is earlier."

john sezso Free

01/08/21 7:27 AM

Post #7,704

Mr. Caloz has entered into a new employment agreement which would tend to predict another years employment with CYTR.
>>>On January 5, 2021, CytRx Corporation (“the Company”) entered into a new Employment Agreement, effective January 1, 2021, with John Y. Caloz, under which we agree to continue to employ Mr. Caloz as our Chief Financial Officer through December 31, 2021<<<

slow_feet

01/08/21 6:16 AM

Post #7,703

8-K: Mr. Caloz has a new parachute, and is predicting he might not be the CFO in the near future?

john sezso Free

01/01/21 8:55 PM

Post #7,702

For the newly curious about CYTR:
CytRx Corporation (OTCQB: CYTR) is a biopharmaceutical company with expertise in discovering and developing new therapeutics principally to treat patients with cancer and neurodegenerative diseases. CytRx's most advanced drug conjugate, aldoxorubicin, is an improved version of the widely used anti-cancer drug doxorubicin and has been outlicensed to ImmunityBio, Inc. In addition, CytRx's other drug candidate, arimoclomol, was sold to Orphazyme (Nasdaq: ORPH) Orphazyme A/S (Nasdaq Copenhagen exchange: ORPHA.CO) in exchange for milestone payments and royalties. Orphazyme is testing arimoclomol in four indications including amyotrophic lateral sclerosis (ALS), Niemann-Pick disease Type C (NPC), Gaucher disease and sporadic Inclusion Body Myositis (sIBM). CytRx Corporation’s website is www.cytrx.com.

slow_feet

12/29/20 10:53 AM

Post #7,701

Re: #7,700: @eom7 - Spoke too soon.

Bouncing back quickly...

eom7

12/29/20 10:49 AM

Post #7,700

Re: #7,696: @slow_feet - Very quiet...and still an MC under 100M.

Spoke too soon.

georgie18

12/29/20 10:18 AM

Post #7,699

Re: #7,698: @eom7 - TY! lol

Enjoy...

eom7

12/29/20 10:16 AM

Post #7,698

Re: #7,697: @georgie18 - Fantastic...call...lol...

TY! lol

Older

LadRx Corp (LADXD)

Followers	208	Posters	563
Posts (Today)	0	Posts (Total)	7747
Created	01/22/05	Type	Free
Moderators

BRUTALLY underpriced Biotech with a laughable market cap of only $10 million trading under their Cash balance of $18.5 million (or Cash untill 2023+) . CYTR has a very large pipeline with multiple Phase 3 und Phase 2 partnered programs ongoing targeting Rare Diseases and Cancer .Most advanced Drug is Arimoclomol for the treatment of Nieman-Pick Disease for which they expect to submit NDA and MAA in Q2 with potential approval in the US and Europe in Q4 this will trigger a $10 million milestone payment to CYTR . More Big News expected within 6 months like the Phase 2 readout of the Gaucher Disease trial and the Phase 3 interim results of sIBM trial (more infos below) .This low float stock has everything to be the next 10+ Bagger at current price the stock is more than a PURE GIFT . STRONG BUY and GL

CytRx (CYTR)

Market-Cap: $9,8 M
Cash: $18,5 M ( Cash untill 2023+ )
Price: $0,29

Shares Out: 33,6 M

Burn-rate: only $1.2 M per Quarter
NO Debt

Upcoming Catalysts of the Rare Disease Pipeline :

Niemann-Pick disease Type C (NPC)--Early access program in January -- NDA/MAA filing in Q2 2020 ---There are no approved treatments for NPC in the USA and only one approved product in Europe. Arimoclomol has been granted Orphan Drug Designation (EU and USA), Rare Pediatric Disease Designation (USA), and Fast Track designation (USA) for the treatment of NPC.

Sporadic Inclusion Body Myositis (sIBM) Phase 2/3 interim results in Q1 2020 -- very large market potential --There are no approved treatments for sIBM. Arimoclomol has been granted Orphan Drug Designation (EU and USA) for the treatment of sIBM.

Amyotrophic Lateral Sclerosis (ALS) interim results Q1/Q2 2020 --very large market potential --Currently, there are only limited treatment options available. Arimoclomol has been granted Orphan Drug Designation (EU and USA) for the treatment of ALS.

Gaucher disease typ III--Phase 2 results in Q1 ---Effective treatments are available for the systemic manifestations of the disease – however, no therapies are available for the neurological symptoms.

Presentation December 2019
http://www.cytrx.com/wp-content/uploads/2019/12/CYTR-Corp-Overview-December-2019-Non-Conf.pdf

CytRx Corporation - Biopharmaceutical Company Discusses Near Term Value from Out-License Deals and Growth Drivers
https://stocknewsnow.com/commentary/ANEWSID26062019100002/VIDEO-CytRx-Corporation-(OTCQB-CYTR)

Orphazyme’s arimoclomol receives US Fast Track designation in sporadic Inclusion Body Myositis
https://finance.yahoo.com/news/orphazyme-arimoclomol-receives-us-fast-060058985.html

Orphazyme receives Breakthrough Therapy Designation for arimoclomol in Niemann-Pick Disease Type C (NPC)
https://finance.yahoo.com/news/orphazyme-receives-breakthrough-therapy-designation-060000973.html